Equities

Armata Pharmaceuticals Inc

Armata Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.33
  • Today's Change0.085 / 3.79%
  • Shares traded8.49k
  • 1 Year change+5.20%
  • Beta0.7912
Data delayed at least 15 minutes, as of Nov 09 2024 01:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments141510
Total Receivables, Net3.36----
Total Inventory------
Prepaid expenses2.27101.72
Other current assets, total--1.942.99
Total current assets192715
Property, plant & equipment, net574738
Goodwill, net3.493.493.49
Intangibles, net101010
Long term investments------
Note receivable - long term------
Other long term assets2.472.431.76
Total assets989670
LIABILITIES
Accounts payable1.591.681.14
Accrued expenses11213.15
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total0.52--0
Total current liabilities16254.81
Total long term debt8200
Total debt8200
Deferred income tax3.083.083.08
Minority interest------
Other liabilities, total293236
Total liabilities1306044
SHAREHOLDERS EQUITY
Common stock0.360.360.27
Additional paid-in capital276275228
Retained earnings (accumulated deficit)(309)(240)(203)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity(32)3625
Total liabilities & shareholders' equity989670
Total common shares outstanding363627
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.